Posted inStock
Morgan Stanley upgrades Vir Biotechnology to ‘overweight,’ raises PT to $20
Investing.com — Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an “overweight” rating, shifting from “equal-weight,” and have also increased their price target to $20 from $10. The…